Medisi America
  • Home
  • We Are
  • Services
  • News
  • Contact Us

Artificial intelligence better than humans at spotting lung cáncer

By Medisi America on 18 junio, 2019

Researchers have used a deep-learning algorithm to detect lung cancer accurately from computed tomography scans. The results of the study indicate that artificial intelligence can outperform human evaluation of these scans.

If you want to read more about this news click here.

https://www.medicalnewstoday.com/articles/325223.php

Posted in News.
Share
←  NewerHuman trials could start soon on Adam’s 3D printed bone grafts
Older  →Stroke significantly increases the risk of dementia

Entradas recientes

  • COFEPRIS Evolves
  • COFEPRIS Challenges 2020
  • ResMed ventilators recall is Class I
  • Finding a non-invasive way to predict effectiveness of cancer therapy.

NEWS

  • Conferences
  • News
  • Science
  • Technology

Deja una respuesta Cancelar la respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Related Posts

  • 30 diciembre, 2019

    Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

    «The Food and Drug Administration (FDA, Agency) identified a list of class I devices and class II devices that are now exempt from premarket notification requirements, subject to certain limitations. FDA published the lists of final determinations in accordance with procedures established by the 21stCentury Cures Act (Cures Act). Although each classification regulation for each …

  • 18 junio, 2019

    More than 1 million Class I medical device units recalled in Q1

    For the third consecutive quarter, more than one million Class I units were recalled during 2019’s Q1. If you want to read more about this news click here. If you want to read more about this news click here.

  • 18 junio, 2019

    New York Times calls for tightened medical device regulation from FDA

    The New York Times last Friday released an editorial calling for improved regulation on medical devices from the FDA, citing a number of recent controversial devices that have made headlines for injuries and deaths related to their use.  If you want to read more about this news click here.

  • 10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …

  • © 2023 MEDISI America - All rights reserved
  • Home
  • We Are
  • Services
  • News
  • Contact Us